Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement

Molecular Medicine

Volumn 9, Issue 9-12, 2003, Pages 193-199

  Johansson, Annika ^a   Möller, Christer ^b   Fogh, Jens ^b   Harper, Pauline ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b HemeBiotech A/S   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; HEME; PHENOBARBITAL; PORPHOBILINOGEN; PORPHOBILINOGEN DEAMINASE; RECOMBINANT ENZYME;

ACUTE INTERMITTENT PORPHYRIA; ANESTHESIA INDUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FEMALE; HEME SYNTHESIS; KIDNEY; LIVER; MALE; MENTAL DISEASE; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PLASMA; PRECURSOR; PRIORITY JOURNAL; URINARY EXCRETION; URINE;

EID: 3042698908     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2004-00002.johansson     Document Type: Article

References (30)

1. Anderson KE, Sassa S, Bishop DF, Desnick RJ. (2001) Disorders of Heme Biosynthesis: X-Linked Sideroblastic Anemia and the Porphyrias. In: The Metabolic and Molecular Bases of Inherited Disease (Vol. 2). Scriver CR, Beaudet AL, Valle D, Sly WS (eds.). McGraw-Hill, New York, USA, pp. 2991-3062.
2. Granick S. (1966) The induction in vitro of the synthesis of delta-aminolevulinic acid synthetase in chemical porphyria: A response to certain drugs, sex hormones, and foreign chemicals. J. Biol. Chem. 241:1359-75.
3. Miyagi K, Cardinal R, Bossenmaier I, Watson CJ. (1971) The serum porphobilinogen and hepatic porphobilinogen deaminase in normal and porphyric individuals. J. Lab. Clin. Med. 78(5):683-95.
4. Schmid R, Schwartz S, Watson CJ. (1954) Porphyrin content of bone marrow and liver in the various forms of porphyria. AMA Arch. Int. Med. 93:167-90.
5. Sweeney VP, Pathak MA, Asbury AK. (1970) Acute intermittent porphyria. Increased ALA-synthetase activity during an acute attack. Brain. 93:369-80.
6. Goldberg A, Rimington C. (1954) Fate of porphobilinogen in the rat. Relation to acute porphyria in man. Lancet 2:172-3.
7. Thunell S. (2000) Porphyrins, porphyrin metabolism and porphyrias. I. Update. Scand. J. Clin. Lab. Invest. 60(7):509-40.
8. Bechara EJH. (1996) Oxidative stress in acute intermittent porphyria and lead poisoning may be triggered by 5-aminolevulinic acid. Braz. J. Med. Biol. Res. 29:841-51.
9. Kauppinen R, Timonen K, Mustajoki P. (1994) Treatment of the porphyrias. Ann. Med. 26:31-8.
10. Tenhunen R, Mustajoki P. (1998) Acute porphyria: treatment with heme. Semin. Liver Dis. 18(1):53-5.
11. Badminton MN, Elder GH. (2002) Management of acute and cutaneous porphyrias. Int. J. Clin. Pract. 56(4):272-8.
12. Sardh E, Rejkjaer L, Harper P, Andersson DE. (2003) First clinical trial of i.v. rhPBGD in healthy subjects with and without diagnosed manifest acute intermittent porphyria (AIP). Physiol. Res. 52:23S.
13. Grandchamp B, De Verneuil H, Beaumont C, Chretien S, Walter O, Nordmann Y. (1987) Tissue-specific expression of porphobilinogen deaminase. Two isoenzymes from o single gene. Eur. J. Biochem. 162(1):105-10.
14. Lindberg RL et al. (1996) Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nat Genet. 12(2):195-9.
15. Jover R, Hoffmann F, Scheffler-Koch V, Lindberg RL. (2000) Limited heme synthesis in porphobilinogen deaminase-deficient mice impairs transcriptional activation of specific cytochrome P450 genes by phenobarbital. Eur. J. Biochem. 267(24):7128-37.
16. Magnussen CR, Levine JB, Doherty JM, Cheesman JO, Tschudy DP (1974). A red cell enzyme method for the diagnosis of acute intermittent porphyria. Blood. 44(6):857-68.
17. Johansson A, Möller C, Gellerfors P, Harper P. (2002) Non-viral mediated gene transfer of porphobilinogen deaminase into mammalian cells. Scand. J. Clin. Lab. Invest. 62(2):105-14.
18. Lentner C. (1984) Physical chemistry composition of blood hematology somatometric data. In: Geigy Scientific Tables (Vol. 3), Ciba-Geigy, pp. 166-7.
19. Davis JR, Andelman SL. (1967) Urinary delta-aminolevulinic acid (ALA) levels in lead poisoning. I. A modified method for the rapid determination of urinary delta-aminolevulinic acid using disposable ion-exchange chromatography columns. Arch. Envir. Health. 15:53-9.
20. Bannerman RM. (1983) Hematology. In: The mouse in medical research (Vol. III). Foster HL, Small JD, Fox JG (eds.). Academic Press, Orlando, FL, USA, pp. 293-312.
21. Sassa S. (1976) Sequential induction of heme pathway enzymes during erythroid differentiation of mouse friend leukemia virus-infected cells. J. Exp. Med. 143:305-15.
22. Lindberg RL et al. (1999) Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J. Clin. Invest. 103(8):1127-34.
23. Harper P, Floderus Y, Andersson C, Möller C, Rejkjaer L, Sardh E, Andersson DE. (2003) Correlation between plasma and urinary levels of porphobilinogen (PBG) and 5-aminolevulinic acid (ALA) in ten asymptomatic gene carriers of acute intermittent porphyria (AIP) with increased porphyrin precursor excretion. Physiol. Res. 52:10S.
24. Bossenmaier I, Cardinal R. (1968) Stability of delta-aminolevulinic acid and porphobilinogen in urine under varying conditions. Clin. Chem. 14:610-4.
25. Elder GH. (1998) Genetic defects in the porphyrias: types and significance. Clin. Dermatol. 16(2):225-33.
26. Thunell S et al. (1995) Markers for vulnerability in acute porphyria. A hypothesis paper. Eur. J. Clin. Chem. Clin. Biochem. 33(4):179-94.
27. Dowdle E, Mustard P, Spong N, Eales L. (1968) The metabolism af [5-14C]delta-aminolaevulinic acid in normal and porphyric human subjects. Clin. Sci. 34:233-51.
28. Mustajoki P, Timonen K, Gorchein A, Seppalainen AM, Matikainen E, Tenhunen R. (1992) Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms. Eur. J. Clin. Invest. 22(6):407-11.
29. Edwards SR, Shanley BC, Reynoldson JA. (1984) Neuropharmacology af delta-aminolaevulinic acid-I. Effect of acute administration in rodents. Neuropharmacology 23:477-81.
30. Feldman DS, Levere RD, Lieberman JS, Cardinal RA, Watson CJ. (1971) Presynaptic neuromuscular inhibition by porphobilinogen and porphobilin. Proc. Nat. Acad. Sci. U.S.A. 68:383-6.